Product Pipeline

Apthera is focused on bringing a pipeline of peptide-based immunotherapies to market to treat cancer. The Company’s lead product, NeuVax™, is currently in clinical testing and has been shown effective at targeting a range of HER2-positive cancers.

Apthera is preparing to launch a large, international, pivotal Phase III clinical trial to evaluate NeuVax for the treatment of early stage, HER2-positive breast cancer. Clinical trials are currently underway to test NeuVax as a treatment for prostate cancer, and to use NeuVax in combination with Herceptin® to target breast cancer.

The following table provides links to more information on each product in Apthera's product pipeline.

Contact us to request more information about our clinical programs.